Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness

Tumor Biology

Volumn 36, Issue 11, 2015, Pages 8593-8600

  Zhang, Zixi ^a   Zhu, Shaojun ^b   Yang, Yang ^a   Ma, Xianjie ^a   Guo, Shuzhong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Melanoma; MMP 12; Prognosis; Progression

Indexed keywords

MACROPHAGE ELASTASE; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CUTANEOUS MELANOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR INVASION; AGED; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN TUMOR;

ADULT; AGED; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 12; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SKIN NEOPLASMS;

EID: 84949086231     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3622-9     Document Type: Article

References (31)

1. Miller AJ, Mihm Jr MC. Melanoma. N Engl J Med. 2006;355:51–65.
2. Rastrelli M, Alaibac M, Stramare R, Chiarion Sileni V, Montesco MC, Vecchiato A, et al. Melanoma m (zero): diagnosis and therapy. ISRN Dermatol. 2013;2013:616170.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin. 2015;65:5–29.
4. Turner RM, Bell KJ, Morton RL, Hayen A, Francken AB, Howard K, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:4641–6.
5. Curti BD. Rapid evolution of combination therapy in melanoma. N Engl J Med. 2014;371:1929–30.
6. Luke JJ, Ott PA. New developments in the treatment of metastatic melanoma—role of dabrafenib-trametinib combination therapy. Drug Healthcare Patient Safety. 2014;6:77–88.
7. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage iii melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28:2452–9.
8. Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol. 2015;38:119–25.
9. Fogarty GB, Hong A. Radiation therapy for advanced and metastatic melanoma. J Surg Oncol. 2014;109:370–5.
10. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to ctla-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99.
11. Ai F, Zhang X, Li X, Qin Z, Ye Q, Tian L, Tang A, Li N, Li G, Ma J, Shen S. Up-regulation of matrix metalloproteinases in a mouse model of chemically induced colitis-associated cancer: The role of micrornas. Oncotarget. 2015;6:5412-25.
12. Zeng XH, Ou ZL, Yu KD, Feng LY, Yin WJ, Li J, et al. Absence of multiple atypical chemokine binders (acbs) and the presence of vegf and mmp-9 predict axillary lymph node metastasis in early breast carcinomas. Med Oncol. 2014;31:145.
13. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, et al. Increased expression of human macrophage metalloelastase (mmp-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract. 2007;203:499–505.
14. Asano T, Tada M, Cheng S, Takemoto N, Kuramae T, Abe M, et al. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res. 2008;146:32–42.
15. Kahlert C, Fiala M, Musso G, Halama N, Keim S, Mazzone M, et al. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Oncotarget. 2014;5:12978–89.
16. Zheng J, Chu D, Wang D, Zhu Y, Zhang X, Ji G, et al. Matrix metalloproteinase-12 is associated with overall survival in chinese patients with gastric cancer. J Surg Oncol. 2013;107:746–51.
17. Ng KT, Qi X, Kong KL, Cheung BY, Lo CM, Poon RT, et al. Overexpression of matrix metalloproteinase-12 (mmp-12) correlates with poor prognosis of hepatocellular carcinoma. Eur J Cancer. 2011;47:2299–305.
18. Hagemann T, Gunawan B, Schulz M, Fuzesi L, Binder C. Mrna expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur J Cancer. 2001;37:1839–46.
19. Gorrin Rivas MJ, Arii S, Furutani M, Harada T, Mizumoto M, Nishiyama H, et al. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: Correlation with angiostatin generation and its clinical significance. Hepatology. 1998;28:986–93.
20. Yang W, Arii S, Gorrin-Rivas MJ, Mori A, Onodera H, Imamura M. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer. 2001;91:1277–83.
21. Hofmann HS, Hansen G, Richter G, Taege C, Simm A, Silber RE, et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11:1086–92.
22. Kerkela E, Ala-aho R, Klemi P, Grenman S, Shapiro SD, Kahari VM, et al. Metalloelastase (mmp-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol. 2002;198:258–69.
23. Kerkela E, Ala-Aho R, Jeskanen L, Rechardt O, Grenman R, Shapiro SD, et al. Expression of human macrophage metalloelastase (mmp-12) by tumor cells in skin cancer. J Investig Dermatol. 2000;114:1113–9.
24. Deraco M, Cabras A, Baratti D, Kusamura S. Immunohistochemical evaluation of minichromosome maintenance protein 7 (mcm7), topoisomerase iialpha, and ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4498-z.
25. Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Cubilla AL, Shih Ie M, et al. Immunohistochemical expression of arid1a in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Hum Pathol. 2015;46:761–6.
26. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27:6199–206.
27. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G, Group EGW. Cutaneous melanoma: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2012;23 Suppl 7:vii86–91.
28. Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27:5445–51.
29. Diaz-Cano SJ. Molecular mechanisms in melanoma. N Engl J Med. 2006;355:1395. author reply 1396.
30. Nabha SM, dos Santos EB, Yamamoto HA, Belizi A, Dong Z, Meng H, et al. Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an mmp-12 dependent manner. Int J Cancer J Int du Cancer. 2008;122:2482–90.
31. Laurenzana A, Biagioni A, D'Alessio S, Bianchini F, Chilla A, Margheri F, et al. Melanoma cell therapy: endothelial progenitor cells as shuttle of the mmp12 upar-degrading enzyme. Oncotarget. 2014;5:3711–27.